Aprea Therapeutics, Inc. (APRE)
0.8065
-0.01
(-1.65%)
USD |
NASDAQ |
Sep 03, 16:00
0.786
-0.02
(-2.54%)
After-Hours: 20:00
Aprea Therapeutics Research and Development Expense (Annual) : 7.043M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 7.043M |
| December 31, 2024 | 9.364M |
| December 31, 2023 | 7.628M |
| December 31, 2022 | 16.40M |
| December 31, 2021 | 23.90M |
| Date | Value |
|---|---|
| December 31, 2020 | 37.88M |
| December 31, 2019 | 20.95M |
| December 31, 2018 | 14.19M |
| December 31, 2017 | 13.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Zymeworks, Inc. | 137.00M |
| Rhythm Pharmaceuticals, Inc. | 166.90M |
| Onconetix, Inc. | -0.0661M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |